We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -0.95% | 9.40 | 9.32 | 9.48 | 9.50 | 9.32 | 9.50 | 708,095 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.74 | 18.85M |
TIDMOBD
RNS Number : 0248A
Oxford BioDynamics PLC
27 May 2021
27 May 2021
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries, the "Group")
Notice of Interim Results
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch(R) 3D genomics platform, expects to announce its interim results for the half-year ended 31 March 2021 on 15 June 2021.
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 Jon Burrows, CEO 518910 Paul Stockdale, CFO Shore Capital - Nominated Adviser and Tel: +44 (0)20 Broker 7408 4090 Advisory: Edward Mansfield / John More Broking: Fiona Conroy Instinctif Partners Tel: +44 (0)20 Melanie Toyne-Sewell / Agnes Stephens 7457 2020 / OxfordBioDynamics@instinctif.com Katie Duffell / Nathan Billis
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit . Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website , www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
Oxford BioDynamics is leveraging its technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, neurodegenerative and autoimmune diseases, to follow its commercial EpiSwitch (R) CST (Covid Severity Test).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORDDLBLFELEBBX
(END) Dow Jones Newswires
May 27, 2021 04:00 ET (08:00 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions